Ayurcann Holdings 株価情報 (OTC: AYURF)

最新ニュース Ayurcann Holdings (OTC:AYURF) 株価情報

Ayurcann Holdings Corp is engaged in providing post-harvest outsourcing solutions to licensed cannabis producers and the manufacture and distribution of cannabis products.

AYURCANN HLDGS CORP by AYURCANN HLDGS CORP.

Ayurcann Holdings Corp

Wells Fargo analyst Michael Turrin maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Overweight and raises the price target from $40 to $42.

News

Price Target

Analyst Ratings

CFLT

Wells Fargo Maintains Overweight on Confluent, Raises Price Target to $42

BMO Capital analyst Brian Pitz maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Market Perform and lowers the price target from $18 to $15.

LYFT

BMO Capital Maintains Market Perform on Lyft, Lowers Price Target to $15

Wells Fargo analyst Ken Gawrelski maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Equal-Weight and raises the price target from $166 to $198.

DASH

Wells Fargo Maintains Equal-Weight on DoorDash, Raises Price Target to $198

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Fed Makes Its Decisions Based On What's Happening In The Economy; Fed Is Reserving Judgment On Likely Effect Of Tariffs Until It Sees The Policies; We Want Reserves To Be Ample; Nothing Good Happens When There's Not Enough Liquidity; All Evidence Suggests Reserves Are Abundant

BMO Capital analyst Joel Jackson maintains Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) with a Market Perform and lowers the price target from $18 to $17.

BMO Capital Maintains Market Perform on Compass Minerals Intl, Lowers Price Target to $17

Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $6 price target.

Reiteration

SAGE

Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $6 Price Target

Wells Fargo analyst Michael Berg maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Equal-Weight and raises the price target from $41 to $48.

KVYO

Wells Fargo Maintains Equal-Weight on Klaviyo, Raises Price Target to $48

BMO Capital analyst Daniel Jester maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Market Perform and lowers the price target from $68 to $60.

BMO Capital Maintains Market Perform on BlackLine, Lowers Price Target to $60

Wedbush analyst Jay McCanless reiterates Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Outperform and maintains $100 price target.

Wedbush Reiterates Outperform on Zillow Gr, Maintains $100 Price Target

Shares of wireless sound technology provider and soon to be doing business as Datavault AI, WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher</a> on Wednesday.
The company revealed a fresh licensing deal with Dolby, enabling Datavault AI to incorporate its patented WiSA E Express multichannel wireless audio software into Android and upcoming <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43656809/datavault-ai-signs-interoperability-license-agreement-with-dolby" rel="noreferrer noopener">Linux-based streaming A/V platforms</a>.
This partnership creates new avenues for WiSA to collaborate directly with system-on-chip providers, broadening its scope and influence.
This updated interoperability agreement makes it easier for brands creating consumer electronics such as TVs, set-top boxes, and projectors to adopt WiSA E Express.
The integration helps manufacturers reduce bill of material costs and speed up their time-to-market. By leveraging Dolby&#8217;s configurations, the integration process is shortened from 12 months to just two months.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/02/43629182/hesais-lidar-takes-bigger-role-byds-gods-eye-advanced-driver-assistance" rel="noreferrer noopener">Hesai&#8217;s Lidar Takes On Bigger Role In BYD&#8217;s &#8216;God&#8217;s Eye&#8217; Advanced Driver Assistance</a>
&#8220;WiSA E Express was created to simplify wireless audio and address the long-standing issue of poor sound quality in TVs and STBs,&#8221; said VP of Business Development and Strategy, Tony Parker.
Android users can download the WiSA app from the Google Play Store. The app features pre-configured Dolby audio settings, automatic detection of WiSA-compatible devices, and regular software updates to enhance the overall user experience.
The wireless audio device market has been growing rapidly, with projections indicating it will reach $154.3 billion by 2030, according to Verified Market Reports.
As part of its goal to advance the wireless audio industry, Datavault AI is trying to innovate with its ADIO inaudible tone technology.
This solution enables real-time data transfer within audio streams, opening up possibilities for targeted advertising, interactive experiences, and deeper audience engagement, thus providing new revenue opportunities for content creators.
Price Action: WISA shares are trading higher by 15.8% at $1.32 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43651110/starbucks-faces-legal-action-over-alleged-discriminatory-hiring-practices" target="_blank" rel="noreferrer noopener">&#8216;Racism Has No Place in Missouri&#8217;: State Attorney General Sues Starbucks Over Hiring Policies</a></li>
</ul>
Image via Shutterstock.

Equities

Movers

General

WISA

WiSA Technologies Teams Up With Dolby To Enhance Wireless Audio; Stock Surges

In December, entrepreneur <a href="https://www.benzinga.com/startups/25/02/43515728/mark-cuban-mocks-meme-coins-but-pitches-one-to-cut-u-s-debt-if-its-a-grift-make-it-a-grift-to-benefit-all-americans">Mark Cuban</a> took to the social media platform <a href="https://bsky.app/profile/mcuban.bsky.social/post/3lcxvn4jb3s23">Bluesky</a> to share his frustrations about the U.S. healthcare system, calling it &#8220;broken.&#8221; He didn't just complain—he offered solutions.&nbsp;
One of his biggest suggestions? Make medical school free for all students. According to Cuban, eliminating tuition costs would encourage more people to become doctors, which could help shorten patient wait times and improve access to care.
He also pointed out a major financial burden on healthcare providers, referring to them as &#8220;subprime lenders.&#8221; In his view, doctors and hospitals are forced to bear the weight of unpaid deductibles, co-pays, and co-insurance.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
When patients can't pay, providers raise prices to cover losses, which only makes healthcare even more expensive. Cuban said on Bluesky, &#8220;This is why healthcare pricing is horrific.&#8221;
The U.S. is known for having the most expensive healthcare system in the world. According to the <a href="https://www.healthsystemtracker.org/indicator/spending/per-capita-spending/?utm_source=chatgpt.com#Total%20national%20health%20expenditures,%20US%20$%20per%20capita,%201970-2022">Peterson-KFF Health System Tracker,</a> in 2022, the country spent approximately $12,255 per person on healthcare—far more than any other high-income nation.&nbsp;
By comparison, Switzerland, the second-highest spender, allocated $8,049 per person, while the average for other wealthy countries was $6,651.&nbsp;
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
Despite these sky-high costs, the U.S. ranks last among 10 peer nations in healthcare performance, according to a <a href="https://www.commonwealthfund.org/publications/fund-reports/2024/sep/mirror-mirror-2024">2024 Commonwealth Fund report</a>. The study found that the U.S. lags in access to care, health equity, and overall outcomes. In other words, Americans are paying more but getting less.
The high cost of healthcare isn't just a policy problem—it's a real struggle for millions of Americans.&nbsp;
A <a href="https://www.kff.org/health-costs/issue-brief/americans-challenges-with-health-care-costs/">Kaiser Family Foundation surve</a>y found that nearly half of U.S. adults say they have trouble affording healthcare, and one in four have faced serious financial problems due to medical bills. Around 25% of adults reported skipping or delaying care because of the cost.
See Also: <a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a>
Medical debt is another major issue. According to a <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1127305/">National Library of Medicine report</a>, about 40% of adults in the U.S. have some form of medical or dental debt, and it's one of the leading causes of personal <a href="https://www.benzinga.com/startups/25/01/42802794/there-wont-be-money-for-social-security-elon-musk-tells-joe-rogan-about-looming-bankruptcy-and-1-1-trillion-interest">bankruptcy</a>. Cuban has spoken out about this, telling Wired <a href="https://www.youtube.com/watch?v=y7TSb9oT1lg">in an interview </a>&nbsp;that without systemic reform, medical debt will continue to cripple many American families.
While the healthcare system has its flaws, there are steps individuals can take to protect themselves from massive medical bills.&nbsp;
Having health insurance is one of the best ways to guard against unexpected expenses. According to the U.S. government, <a href="https://www.healthcare.gov/young-adults/ready-to-apply/#:~:text=A%20broken%20leg%20can%20cost,can%20really%20limit%20your%20options.">treating a broken leg can cost up to $7,500,</a> while the American Association for Cancer Research says <a href="https://www.aacr.org/patients-caregivers/progress-against-cancer/the-rising-cost-of-cancer-care/">cancer treatment is at least $100,000</a> and expected to exceed $245 billion by 2030.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>

Startups

Mark Cuban Says U.S. Healthcare Is 'Horrific'—Calls for Free Medical School to Fix Doctor Shortages and Soaring Costs

Financial giants have made a conspicuous bullish move on Affirm Holdings. Our analysis of options history for Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) revealed 15 unusual trades.
Delving into the details, we found 53% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $82,836, and 13 were calls, valued at $1,316,442.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $62.5 and $90.0 for Affirm Holdings, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Affirm Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Affirm Holdings's significant trades, within a strike price range of $62.5 to $90.0, over the past month.
<h3>Affirm Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739375180_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.55</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$75.00</td>
<td>$325.0K</td>
<td>1.5K</td>
<td align="right">640</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$11.9</td>
<td>$11.65</td>
<td>$11.9</td>
<td>$75.00</td>
<td>$238.0K</td>
<td>2.6K</td>
<td align="right">201</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$12.4</td>
<td>$11.9</td>
<td>$12.15</td>
<td>$90.00</td>
<td>$121.5K</td>
<td>737</td>
<td align="right">200</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$75.00</td>
<td>$109.2K</td>
<td>1.5K</td>
<td align="right">887</td>
</tr>
<tr>
<td>AFRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$19.5</td>
<td>$17.1</td>
<td>$18.64</td>
<td>$65.00</td>
<td>$93.2K</td>
<td>1.1K</td>
<td align="right">50</td>
</tr>
</tbody>
</table>

<h3>About Affirm Holdings</h3>
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
Following our analysis of the options activities associated with Affirm Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Affirm Holdings Standing Right Now?</h3>
<ul>
<li>With a volume of 3,061,175, the price of AFRM is down -2.86% at $75.79. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Affirm Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

AFRM

Affirm Holdings's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bullish approach towards Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CORZ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Core Scientific. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 44% bearish. Among these notable options, 2 are puts, totaling $259,262, and 7 are calls, amounting to $341,604.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $15.0 for Core Scientific over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Core Scientific's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Core Scientific's whale trades within a strike price range from $7.0 to $15.0 in the last 30 days. 
<h3>Core Scientific Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739375175_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$12.00</td>
<td>$222.6K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$11.00</td>
<td>$76.8K</td>
<td>265</td>
<td>243</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.1</td>
<td>$2.07</td>
<td>$2.1</td>
<td>$10.00</td>
<td>$63.0K</td>
<td>2.4K</td>
<td>301</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$8.00</td>
<td>$59.5K</td>
<td>8.0K</td>
<td>90</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.8</td>
<td>$5.88</td>
<td>$7.00</td>
<td>$44.2K</td>
<td>18.2K</td>
<td>125</td>
</tr>
</tbody>
</table>

<h3>About Core Scientific</h3>
Core Scientific Inc is engaged in Blockchain and AI Infrastructure, Digital Asset Self-Mining, Premium Hosting, Blockchain Technology, and Artificial Intelligence related services. The business operates in two segments being; Equipment Sales and Hosting which consists of blockchain infrastructure, third-party hosting business and equipment sales to customers. Mining segment consists of digital asset mining for its account. The blockchain business generates revenue from the sale of consumption-based contracts and by providing hosting services. The digital asset mining segment earns revenue from operating a firm's owned computer equipment as part of a pool of users that process transactions conducted on one or more blockchain networks. In exchange, it receives digital currency assets.
In light of the recent options history for Core Scientific, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Core Scientific's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,500,234, with CORZ's price down by -3.1%, positioned at $11.88.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Core Scientific</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $21.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Craig-Hallum lowers its rating to Buy with a new price target of $24. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $18. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Core Scientific with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Core Scientific, Inc. - Class A Common Stock

CORZ

Looking At Core Scientific's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Tenet Healthcare.
Looking at options history for Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $451,318 and 2, calls, for a total amount of $70,520.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $140.0 for Tenet Healthcare during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Tenet Healthcare's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Tenet Healthcare's substantial trades, within a strike price spectrum from $130.0 to $140.0 over the preceding 30 days.
<h3>Tenet Healthcare Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739375169_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$11.82</td>
<td>$140.00</td>
<td>$83.0K</td>
<td align="right">521</td>
<td align="right">70</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$12.7</td>
<td>$11.6</td>
<td>$12.06</td>
<td>$140.00</td>
<td>$82.4K</td>
<td align="right">521</td>
<td align="right">72</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.2</td>
<td>$8.4</td>
<td>$8.75</td>
<td>$140.00</td>
<td>$61.0K</td>
<td align="right">426</td>
<td align="right">172</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.0</td>
<td>$8.3</td>
<td>$8.57</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">171</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.4</td>
<td>$8.3</td>
<td>$8.81</td>
<td>$135.00</td>
<td>$60.3K</td>
<td align="right">612</td>
<td align="right">173</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
In light of the recent options history for Tenet Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Tenet Healthcare Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,157,418, with THC's price down by -6.25%, positioned at $130.16.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tenet Healthcare, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Smart Money Is Betting Big In THC Options

Wells Fargo analyst Andrew Bauch maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Equal-Weight and lowers the price target from $88 to $80.

Wells Fargo Maintains Equal-Weight on Fidelity National Info, Lowers Price Target to $80

BMO Capital analyst Etzer Darout reiterates Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Outperform and lowers the price target from $88 to $82.

ARVN

BMO Capital Reiterates Outperform on Arvinas, Lowers Price Target to $82

<ul>
<li>Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure</li>
<li>Hypertension is the leading cause of diastolic dysfunction; both conditions are common in older patients and contribute to the development of heart failure</li>
</ul>
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation ("AVIM") therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics ("THT") 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic ("Echo") markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
The presentation titled "Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction" is being delivered in a late-breaking clinical science session at THT by Marat Fudim, M.D., M.H.S.​ Advanced Heart Failure Cardiologist, Duke Health on Wednesday, February 12, 2025, at 10:43am ET.

Biotech

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed To Present Data Demonstrating Impact Of AVIM Therapy On Diastolic Dysfunction, A Key Driver Of Heart Failure Progression, As Late-Breaking Science At The THT 2025 Conference

On Wednesday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;and Xilio Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654121/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-a" rel="noreferrer noopener">leveraging Xilio&#8217;s proprietary technology</a>.
Xilio has developed a proprietary, clinically validated platform technology for tumor-activated biologics.
The company is advancing a pipeline of clinical and preclinical immunotherapies, including masked multispecific molecules, designed to achieve tumor-selective activation by leveraging masking and other unique components that are optimized for the specific target.
The action allows focused activity within the tumor microenvironment to minimize systemic adverse events.
Under the terms of the agreement, Xilio will receive $52.0 million in upfront payments, including a $10 million equity investment, and will be eligible to receive up to approximately $2.1 billion in contingent payments for option-related fees and milestones plus tiered royalties.
Concurrently, Xilio Therapeutics announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen for prostate cancer (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654150/xilio-therapeutics-announces-multiple-masked-t-cell-engager-programs" rel="noreferrer noopener">antigen of prostate 1 (STEAP1)</a>.
<ul>
<li>Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 and submitting an investigational new drug application (IND) in the first quarter of 2027.</li>
<li>CLDN18.2 has broad potential as a T cell engager target for gastric, pancreatic, esophageal, and lung cancers. Xilio anticipates nominating a development candidate for its CLDN18.2 program in the ATACR format in the fourth quarter of 2025 and submitting an IND in the second quarter of 2027.</li>
<li>STEAP1 has broad potential as a T cell engager target for prostate, colorectal, and lung cancers. Xilio anticipates nominating a development candidate for its STEAP1 program in the SEECR format in the first half of 2026 and submitting an IND in the second half of 2027.</li>
</ul>
Xilio anticipates that its existing cash and cash equivalents and the upfront payments under the agreement with AbbVie will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2026.
Price Action: XLO stock is up 116.10% at $1.42 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43658118/martin-marietta-increases-revenue-expands-margins-ceo-expects-data-center-demand-to-offset-ongoing-softness" target="_blank" rel="noreferrer noopener">Martin Marietta Increases Revenue, Expands Margins: CEO Expects &#8216;Data Center Demand To Offset Ongoing Softness&#8217;</a></li>
</ul>

Health Care

Contracts

Trading Ideas

ABBV

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Guggenheim analyst Ronald Jewsikow reiterates AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) from Buy to Buy.

Guggenheim Reiterates Buy on AutoNationto Buy

Fed Chair Powell Says Before There Was A Fed Vice Chair For Supervision, Policymaking At Fed Was Less Volatile; We Can Get Our Work Done Even After Barr's Resignation As VC Of Supervision

Ayurcann Holdings reports Q2 results

Ayurcann Holdings reports Q3 results

Ayurcann terminates business combination

AYURF

Press Releases

AYURCANN REPORTS RECORD SALES IN Q2 2024 FEATURING A 141% INCREASE IN GROSS REVENUE

AYURCANN REPORTS RECORD SALES IN Q3 2024 OF $11,655,360  FEATURING A 97% INCREASE IN GROSS REVENUE

Ayurcann Holdings Corp is entering into a business combination with Arogo Capital Acquisition Corp. and its subsidiaries at a combined enterprise value estimated to be U.S. $210 million.

Comments

Ayurcann Holdings

ニュース

最新ニュース Ayurcann Holdings (OTC:AYURF) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル